Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
8.79
-0.12 (-1.35%)
At close: Aug 13, 2025, 4:00 PM
8.80
+0.01 (0.11%)
Pre-market: Aug 14, 2025, 8:43 AM EDT
Emergent BioSolutions Employees
Emergent BioSolutions had 900 employees as of December 31, 2024. The number of employees decreased by 700 or -43.75% compared to the previous year.
Employees
900
Change (1Y)
-700
Growth (1Y)
-43.75%
Revenue / Employee
$946,222
Profits / Employee
$155,000
Market Cap
468.96M
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
EBS News
- 1 day ago - Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally - Seeking Alpha
- 6 days ago - Emergent BioSolutions Inc. (EBS) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 days ago - Emergent BioSolutions Reports Second Quarter 2025 Financial Results - GlobeNewsWire
- 17 days ago - Emergent Applauds Availability of Over-the-Counter Naloxone in U.S. House of Representatives - GlobeNewsWire
- 17 days ago - New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox - GlobeNewsWire
- 4 weeks ago - Emergent BioSolutions to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewsWire
- 5 weeks ago - Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016® [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts - GlobeNewsWire
- 6 weeks ago - Emergent BioSolutions Expands NARCANDirect® to Offer KLOXXADO® (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate - GlobeNewsWire